List of Excipients in Branded Drug CIPROFLOXACIN IN DEXTROSE

Generic Drugs Containing CIPROFLOXACIN IN DEXTROSE

Company	Ingredient	NDC	Excipient
Hospira Inc	ciprofloxacin	0409-2300	DEXTROSE MONOHYDRATE
Hospira Inc	ciprofloxacin	0409-2300	HYDROCHLORIC ACID
Hospira Inc	ciprofloxacin	0409-2300	LACTIC ACID

What are the Most Frequently-Used Excipients in CIPROFLOXACIN IN DEXTROSE?

# Of NDCs	Excipient
2	DEXTROSE MONOHYDRATE
2	HYDROCHLORIC ACID
2	LACTIC ACID

Ciprofloxacin in Dextrose Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Ciprofloxacin in dextrose is a mature intravenous, ready-to-use fluoroquinolone product with limited conventional patent value and greater commercial potential in formulation execution, hospital supply reliability, packaging, and procurement economics. The principal opportunity is a stable premixed IV presentation, typically ciprofloxacin 2 mg/mL in 5% dextrose, supplied in 100 mL and 200 mL containers.

The product is not a biologic and has no biosimilar pathway. Generic competition is established. Current differentiation depends on container technology, shelf life, low extractables, manufacturing cost, shortage resilience, and institutional contracting rather than molecule protection.

What is ciprofloxacin in dextrose?

Ciprofloxacin in dextrose is an intravenous solution containing ciprofloxacin, usually at 2 mg/mL, in a 5% dextrose vehicle. Common dose presentations include:

Presentation	Ciprofloxacin content	Dextrose vehicle	Typical administration
100 mL bag	200 mg	5% dextrose	IV infusion
200 mL bag	400 mg	5% dextrose	IV infusion

The reference product, Cipro I.V., was marketed by Bayer. FDA labeling identifies dextrose as the principal vehicle and includes excipients used to adjust and maintain solution pH, such as lactic acid and hydrochloric acid, depending on the specific product and label version (U.S. Food and Drug Administration [FDA], 2023a).

Ciprofloxacin IV is used for susceptible bacterial infections when oral administration is not appropriate. Fluoroquinolone safety restrictions, including risks of tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, QT prolongation, dysglycemia, and aortic complications, affect prescribing and demand (FDA, 2018).

What excipients protect ciprofloxacin in dextrose formulations?

The excipient system has four principal functions: pH control, chemical stability, compatibility with the active ingredient, and control of container interaction.

Dextrose as the primary vehicle

Dextrose 5% in water provides an isotonic or near-isotonic infusion vehicle and supports hospital workflow by combining hydration fluid and antibiotic administration in one package. The vehicle also affects:

• Ciprofloxacin solubility
• Solution pH
• Osmolality
• Chemical degradation
• Compatibility with infusion sets
• Patient tolerability
• Container adsorption and permeability

A dextrose vehicle can create different stability and compatibility conditions from a sodium chloride vehicle. A manufacturer cannot assume that performance in 0.9% sodium chloride will transfer directly to 5% dextrose.

Acidifying agents and pH control

Ciprofloxacin has limited aqueous solubility at neutral pH. Commercial IV solutions therefore use an acidic formulation environment. Lactic acid and hydrochloric acid may be used to establish the target pH and maintain ciprofloxacin in solution.

The pH window is a central development variable because it affects:

• Precipitation risk
• Ciprofloxacin degradation
• Color formation
• Compatibility with other IV products
• Infusion-site tolerability
• Container closure performance

The formulation should be evaluated across manufacturing, storage, transport, and administration conditions. A narrow laboratory pH target is insufficient if the product experiences temperature excursions or prolonged storage in hospital inventory.

Water quality and process controls

Water for Injection is the principal solvent. Control of bioburden, endotoxin, particulate matter, and dissolved oxygen is central to the product’s quality profile. Terminal sterilization may be attractive for manufacturing simplicity, but the formulation and container must tolerate the selected sterilization cycle.

Where terminal sterilization is unsuitable, aseptic processing increases facility, validation, and release-testing requirements. The choice affects cost of goods and the ability to compete in hospital tenders.

Excipient and material compatibility

The final formulation must be assessed with:

• PVC and non-PVC infusion bags
• Multilayer polyolefin containers
• Elastomeric ports and stoppers
• Administration tubing
• Light exposure
• Oxygen exposure
• Sterilization conditions
• Freezing and thawing
• Temperature excursions

The label should state compatible and incompatible infusion solutions and drugs. Ciprofloxacin may form precipitates with alkaline solutions or products containing certain multivalent cations. Hospital-use instructions are therefore part of the commercial product strategy, not only a regulatory requirement (FDA, 2023a).

What formulations are protected by ciprofloxacin in dextrose patents?

The original ciprofloxacin compound and early injectable formulations are long past their primary patent and regulatory exclusivity periods. The commercial value of a new ciprofloxacin-in-dextrose product is unlikely to depend on blocking the active ingredient.

Potentially protectable subject matter includes:

IP category	Potential scope	Commercial strength
Composition patent	Novel excipient ratio, pH, stabilizer, or impurity-control system	Low to moderate unless performance is unexpected
Formulation patent	Defined ciprofloxacin concentration and stability profile	Moderate if supported by comparative data
Container patent	Bag, port, multilayer film, or oxygen-barrier structure	Moderate
Manufacturing patent	Sterilization, filling, degassing, or impurity-control process	Moderate
Method-of-use patent	New clinical use or dosing regimen	Low for established IV ciprofloxacin uses
Trade secret	Process parameters, hold times, sterilization controls, and scale-up know-how	High practical value, limited exclusionary reach
Trademark	Product name and packaging identity	Limited protection against generic substitution

A formulation patent is more defensible when it establishes an unexpected result, such as materially improved stability, lower impurity formation, reduced precipitation, or extended shelf life without introducing a clinically meaningful excipient burden. A patent that merely recites ciprofloxacin, dextrose, an acid, and water within routine ranges faces substantial obviousness risk.

Patent expiration and current patent exposure

No active composition-of-matter exclusivity remains for ciprofloxacin. Historical patents associated with ciprofloxacin products and early dosage forms have expired. A current developer should focus on later-filed formulation, process, container, or use patents rather than the ciprofloxacin molecule.

The FDA Orange Book remains the primary source for patent listings and regulatory exclusivity associated with approved drug products. Patent status must be reviewed by product, NDA, dosage form, and listed patent rather than inferred from the active ingredient alone (FDA, 2024a).

What is the Orange Book status of ciprofloxacin in dextrose?

Ciprofloxacin in dextrose is a conventional small-molecule injectable product. The relevant regulatory questions are:

1. Whether the reference NDA remains listed as the reference product.
2. Whether the specific presentation has current patent listings.
3. Whether approved ANDA products are therapeutically equivalent.
4. Whether any listed patent requires a Paragraph IV certification.
5. Whether FDA exclusivity remains active.

For a mature ciprofloxacin IV product, regulatory exclusivity is generally no longer the principal barrier. A prospective ANDA applicant should verify the current Orange Book entry, listed patents, dosage-form coding, and therapeutic-equivalence codes at the time of filing (FDA, 2024a).

When did ciprofloxacin in dextrose lose exclusivity?

Ciprofloxacin in dextrose lost meaningful market exclusivity years ago. The product is now in the generic lifecycle, with competition from multiple injectable manufacturers and contract suppliers.

The original product’s economic protection ended through the combined expiration of:

• Ciprofloxacin compound patents
• Early formulation and product patents
• Statutory five-year new chemical entity exclusivity
• Any applicable patent-term extensions
• Pediatric exclusivity periods, where granted

The current commercial issue is not loss of exclusivity timing. It is whether a supplier can obtain approval, maintain sterile manufacturing capacity, secure dextrose and packaging inputs, and win hospital purchasing contracts.

Which companies compete in ciprofloxacin in dextrose?

Competition includes branded legacy suppliers, generic injectable manufacturers, and contract manufacturing organizations. The market is commonly served through products supplied in flexible infusion bags, bottles, or other ready-to-use containers.

Representative competitive groups include:

Competitor category	Commercial position
Bayer legacy product	Reference-brand history; limited current patent leverage
Large generic injectable companies	Broad hospital portfolios and tender capabilities
Specialty sterile manufacturers	Focus on supply reliability and selected presentations
Contract manufacturing organizations	Development and manufacturing platform for third parties
Regional suppliers	Geographic or government-contract advantages

The relevant competitive comparison is often between ciprofloxacin in dextrose and ciprofloxacin in sodium chloride, as well as other IV antibiotics used for overlapping indications. Hospital systems may prefer a product that reduces pharmacy compounding, even when the active ingredient is therapeutically interchangeable.

What commercial opportunities exist for ciprofloxacin in dextrose?

Ready-to-use hospital bags

The strongest opportunity is a ready-to-administer product that eliminates pharmacy compounding. Benefits include:

• Lower preparation labor
• Lower compounding error risk
• Reduced pharmacy cleanroom workload
• Faster administration
• Standardized dosing
• Easier inventory management

The commercial value is highest in hospitals, emergency departments, outpatient infusion centers, and government procurement systems.

Dual-source and shortage-resilient supply

Sterile injectable shortages can create purchasing opportunities even for mature products. A supplier with redundant manufacturing sites, validated alternate packaging, and reliable active pharmaceutical ingredient supply can win contracts from buyers seeking a second source.

Supply-chain differentiation may include:

• Domestic or regional fill-finish capacity
• Multiple qualified dextrose suppliers
• Dual-source container films
• Safety stock for government tenders
• Short lead times
• Temperature-controlled distribution controls

Alternative container systems

A non-PVC or low-extractables container may support hospital conversion where buyers have concerns about plasticizers, adsorption, environmental policy, or compatibility. The benefit must be demonstrated through extractables and leachables testing, stability data, and administration-set compatibility.

Extended shelf life

Shelf life beyond the market standard can reduce hospital waste and improve inventory economics. A successful program should quantify:

• Assay retention
• Ciprofloxacin-related impurities
• pH drift
• Color change
• Subvisible particles
• Container integrity
• Sterility
• Endotoxin
• Compatibility after simulated shipping

Shelf-life claims are commercially meaningful only if they survive real-world temperature and handling conditions.

Smaller or specialized presentations

Potential niche presentations include:

• 50 mL bags for selected pediatric or controlled-volume use
• 100 mL presentations for 200 mg doses
• 200 mL presentations for 400 mg doses
• High-barrier bags for extended storage
• Packaging optimized for automated dispensing systems

Dose-volume changes may require careful clinical and regulatory assessment because they can alter administration time, osmolarity, and hospital protocols.

What regulatory pathway applies to a new ciprofloxacin in dextrose product?

A conventional generic product would generally be developed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Injectable solutions may qualify for an ANDA when they match the reference product in active ingredient, dosage form, strength, route, and relevant inactive-ingredient characteristics.

For parenteral products, FDA evaluates formulation sameness and may permit reliance on the reference product’s clinical efficacy and safety findings when the generic meets applicable requirements. Differences in excipients can require justification, particularly where they may affect safety, tolerability, stability, or bioequivalence (FDA, 2023b).

A materially different formulation, new container technology, or new route may create a 505(b)(2) pathway rather than a standard ANDA. That route can support differentiated products but usually increases clinical, regulatory, and development costs.

Key development requirements include:

• Sterility assurance
• Endotoxin control
• Particulate control
• Extractables and leachables
• Container-closure integrity
• Stability under labeled conditions
• Photostability
• Shipping validation
• Infusion-set compatibility
• In-use stability
• Microbiological risk assessment
• Labeling for storage and administration

Are Paragraph IV challenges relevant to ciprofloxacin in dextrose?

Paragraph IV litigation is possible if the Orange Book lists an unexpired patent for the specific reference product. For a mature ciprofloxacin IV product, the likelihood of a meaningful active patent barrier is low, but the Orange Book must be checked at filing.

An ANDA applicant has four certification options under the Hatch-Waxman framework:

• Paragraph I: no patent information has been filed
• Paragraph II: the patent has expired
• Paragraph III: approval is sought after patent expiration
• Paragraph IV: the patent is invalid, unenforceable, or will not be infringed

A Paragraph IV certification can trigger patent litigation and a potential 30-month stay under applicable statutory conditions. The risk depends on the exact patent claims, listed NDA, filing date, and litigation history. A formulation or container patent filed after the original product may still create a narrower dispute even when the ciprofloxacin molecule is unprotected (FDA, 2024b).

What patent litigation and settlement risks affect the product?

The litigation profile is generally lower than for high-value branded medicines because ciprofloxacin IV has low unit economics and broad generic availability. Potential disputes may still involve:

• Formulation patents
• Premixed infusion-bag patents
• Container and port configurations
• Manufacturing-process patents
• False patent certification allegations
• Labeling carve-outs for method-of-use claims
• Product-specific trade dress or trademark claims

Settlement value is usually limited unless a patent owner controls a commercially important formulation or supply channel. A generic entrant should conduct a freedom-to-operate review covering both ciprofloxacin-specific patents and platform patents held by infusion-bag manufacturers.

How strong is the patent estate for ciprofloxacin in dextrose?

The underlying patent estate is weak for exclusivity purposes and potentially useful only for narrow product differentiation.

Factor	Assessment
Active-ingredient protection	Expired
Regulatory exclusivity	Expired
Broad formulation protection	Difficult to obtain or enforce
Container protection	Possible but design-around risk is high
Manufacturing protection	Potentially useful as a trade secret
Method-of-use protection	Limited for established indications
Generic entry barrier	Low
Commercial defensibility	Dependent on cost, quality, and supply

A new patent strategy should prioritize measurable technical advantages rather than broad claims to a known ciprofloxacin-dextrose solution.

What manufacturing and IP barriers exist?

Sterile manufacturing is the principal barrier. The technical challenges include:

1. Maintaining ciprofloxacin solubility over the full shelf life.
2. Preventing precipitation during cold storage and temperature excursions.
3. Controlling acidic pH without increasing degradation.
4. Managing bag-film permeability and leachables.
5. Achieving consistent terminal sterilization or aseptic assurance.
6. Demonstrating compatibility with administration sets.
7. Maintaining low particulate levels at commercial scale.
8. Controlling fill volume and container integrity.

These barriers are operational rather than molecule-specific. They can support trade secrets, process know-how, and customer qualification advantages, but they do not necessarily create durable patent exclusivity.

How does ciprofloxacin in dextrose compare with ciprofloxacin in sodium chloride?

Attribute	Ciprofloxacin in 5% dextrose	Ciprofloxacin in 0.9% sodium chloride
Primary vehicle	Dextrose	Sodium chloride
Hospital use	Ready-to-use antibiotic infusion	Ready-to-use antibiotic infusion
Key formulation issue	Dextrose stability and container interaction	Salt compatibility and osmolality
Patient considerations	Adds glucose load	Adds sodium load
Commercial positioning	Useful where dextrose-based infusion is preferred	Useful where sodium load is preferred
Patent position	Mature generic product	Mature generic product
Main differentiation	Packaging, stability, supply	Packaging, stability, supply

The two products are not automatically interchangeable in every clinical or procurement setting. Hospitals may specify one vehicle because of patient population, fluid restrictions, glucose management, sodium management, or formulary policy.

What revenue exposure and launch scenarios exist?

Product-level revenue for ciprofloxacin in dextrose is generally not reported separately by originator companies. Public disclosures usually aggregate products by business segment or therapeutic area. Revenue forecasting should therefore use institutional volume, tender pricing, presentation mix, and market share rather than historical branded revenue.

A generic launch has three practical scenarios:

Launch scenario	Conditions	Expected commercial profile
Price-led entry	Multiple approved suppliers and no shortage	Low margin, high tender sensitivity
Supply-led entry	Incumbent shortages or unreliable supply	Faster account wins and improved pricing
Differentiated packaging	Non-PVC bag, longer shelf life, or better handling	Moderate premium if hospital conversion costs are low

A new entrant should avoid relying on premium pricing unless it can document lower total cost of ownership. The strongest value proposition is often reduced pharmacy preparation, fewer discarded doses, lower storage complexity, and dependable delivery.

Key Takeaways

• Ciprofloxacin in dextrose is a mature generic IV product, commonly supplied as 200 mg/100 mL and 400 mg/200 mL.
• Dextrose, pH-adjusting acids, water quality, and container materials determine formulation performance.
• Ciprofloxacin compound and early product exclusivity have expired.
• Current Orange Book and Paragraph IV risk is likely limited but must be assessed for the exact reference product and presentation.
• Biosimilar competition is irrelevant because ciprofloxacin is a small-molecule drug.
• The strongest commercial opportunities involve ready-to-use bags, shortage-resilient supply, non-PVC packaging, extended shelf life, and lower hospital preparation costs.
• Sterile manufacturing, stability, container compatibility, and supply reliability are more important barriers than active-ingredient IP.
• Formulation patents require comparative data showing unexpected stability, impurity, compatibility, or usability benefits.
• Product-level revenue is not generally disclosed separately, so commercial modeling should rely on tender volume, pricing, and institutional share.

FAQs

Is ciprofloxacin in dextrose still protected by a composition-of-matter patent?

No. Ciprofloxacin’s original active-ingredient patent protection has expired. Any current protection would more likely involve a specific formulation, container, process, or use.

Can ciprofloxacin in dextrose be sold as an ANDA product?

A conventional equivalent injectable solution may generally be pursued through an ANDA, subject to FDA requirements for formulation sameness, sterility, stability, container closure, and labeling.

Does dextrose improve ciprofloxacin antimicrobial activity?

No. Dextrose is primarily the infusion vehicle. It supports administration and product presentation but is not intended to increase ciprofloxacin’s antibacterial activity.

Can a manufacturer patent a longer shelf life for ciprofloxacin in dextrose?

Potentially, but a patent requires more than a longer claimed storage period. The applicant would need a patentable formulation or process and data showing a meaningful, non-obvious stability advantage.

Is ciprofloxacin in dextrose interchangeable with ciprofloxacin in sodium chloride?

Clinical and regulatory interchangeability depends on the specific approved products, labels, concentration, administration instructions, and institutional policy. The vehicles impose different sodium, glucose, compatibility, and patient-management considerations.

References

1. U.S. Food and Drug Administration. (2018). FDA updates warnings for fluoroquinolone antibiotics. https://www.fda.gov/

2. U.S. Food and Drug Administration. (2023a). Ciprofloxacin injection, solution: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2023b). ANDAs for certain highly purified synthetic peptides. FDA guidance and generic drug development materials. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024b). Hatch-Waxman patent certification and Paragraph IV provisions. https://www.fda.gov/

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Sterile preparations and pharmaceutical compounding standards. USP.